Overview

Lumykras is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC) when the cancer is advanced, and its cells have a particular genetic change. The change is in the gene KRAS and is known as ‘KRAS G12C’. Lumykras is given when the disease has progressed after receiving systemic treatment (treatment affecting the whole body).

Lumykras contains the active substance sotorasib.

The medicine can only be obtained with a prescription, and treatment with Lumykras should be started by a doctor who is experienced in using cancer medicines.

The patient’s cancer should be tested before starting treatment to confirm it has the genetic change affecting KRAS (KRAS G12C).

Lumykras is available as tablets and is taken by mouth. The recommended dose is 960 mg once per day. Treatment is continued until the disease gets worse or side effects become too severe.

If certain side effects develop, the doctor may decide to reduce the dose to 480 mg once per day and then, if needed, to 240 mg once per day. Treatment should be stopped if side effects are too great at the lowest dose (240 mg).

For more information about using Lumykras, see the package leaflet or contact your doctor or pharmacist.

Genetic changes to the KRAS gene can produce an altered protein that causes the uncontrolled growth of cancer cells. The active substance in Lumykras, sotorasib, attaches to this altered protein inside cancer cells. This blocks the protein from acting, interrupting the chemical messages the cancer cells need for growing and spreading, and it also encourages processes that cause the cancer cells to die.

In one main study involving 124 patients, Lumykras was effective in treating adults with NSCLC with the KRAS G12C genetic change whose disease had progressed after previously being treated with other cancer medicines. Lumykras was not compared with any other treatment or placebo (a dummy treatment).

Response to treatment (shrinkage in the size of the cancer) was assessed using body scans. Around 37% (46 out of 124) of the patients showed partial or complete cancer shrinkage after treatment with Lumykras. On average, responses lasted for just over 11 months.

The most common side effects with Lumykras (which may affect more than 1 in 5 people) are diarrhoea, nausea (feeling sick) and tiredness. The most common severe side effects with Lumykras (which may affect up to 1 in 100 people) are increased levels of certain liver enzymes (a sign of possible liver problems) and liver injury. For the full list of side effects and restrictions of Lumykras, see the package leaflet.

There are currently few treatment options for patients with advanced NSCLC with KRAS G12C mutations for whom the cancer has progressed after systemic treatment with cancer medicines, and current treatments have limited effectiveness. Although the main study did not compare Lumykras with another cancer treatment, it showed that the medicine was effective at treating the cancer including in patients whose cancer had progressed after several different treatments. In general, Lumykras’ side effects were considered manageable.

The European Medicines Agency, therefore, decided that Lumykras’ benefits are greater than its risks and it can be authorised for use in the EU.

Lumykras has been given ‘conditional authorisation’. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the European Medicines Agency will review any new information that becomes available and this overview will be updated as necessary.

Since Lumykras has been given conditional authorisation, the company that markets Lumykras will provide further information from an ongoing study. The study will compare the efficacy and safety of Lumykras in treating previously treated NSCLC with KRAS G12C mutation with those of another cancer medicine, docetaxel.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lumykras have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lumykras are continuously monitored. Suspected side effects reported with Lumykras are carefully evaluated and any necessary action taken to protect patients.

Lumykras received a conditional marketing authorisation valid throughout the EU on 06 January 2022.

български (BG) (164.27 KB - PDF)

View

español (ES) (132.2 KB - PDF)

View

čeština (CS) (155.61 KB - PDF)

View

dansk (DA) (132.71 KB - PDF)

View

Deutsch (DE) (136.13 KB - PDF)

View

eesti keel (ET) (127.13 KB - PDF)

View

ελληνικά (EL) (163.96 KB - PDF)

View

français (FR) (133.65 KB - PDF)

View

hrvatski (HR) (154.12 KB - PDF)

View

italiano (IT) (131.69 KB - PDF)

View

latviešu valoda (LV) (160.1 KB - PDF)

View

lietuvių kalba (LT) (152.4 KB - PDF)

View

magyar (HU) (154.13 KB - PDF)

View

Malti (MT) (155.94 KB - PDF)

View

Nederlands (NL) (133.53 KB - PDF)

View

polski (PL) (156.97 KB - PDF)

View

português (PT) (133.16 KB - PDF)

View

română (RO) (143.97 KB - PDF)

View

slovenčina (SK) (154.19 KB - PDF)

View

slovenščina (SL) (153.71 KB - PDF)

View

Suomi (FI) (129.23 KB - PDF)

View

svenska (SV) (130.92 KB - PDF)

View

Product information

български (BG) (490.73 KB - PDF)

View

español (ES) (322 KB - PDF)

View

čeština (CS) (401.95 KB - PDF)

View

dansk (DA) (398.6 KB - PDF)

View

Deutsch (DE) (428.7 KB - PDF)

View

eesti keel (ET) (315.07 KB - PDF)

View

ελληνικά (EL) (412.95 KB - PDF)

View

français (FR) (474.84 KB - PDF)

View

hrvatski (HR) (465.29 KB - PDF)

View

íslenska (IS) (402.94 KB - PDF)

View

italiano (IT) (418.08 KB - PDF)

View

latviešu valoda (LV) (470.21 KB - PDF)

View

lietuvių kalba (LT) (471.58 KB - PDF)

View

magyar (HU) (473.91 KB - PDF)

View

Malti (MT) (541.57 KB - PDF)

View

Nederlands (NL) (414.79 KB - PDF)

View

norsk (NO) (394.13 KB - PDF)

View

polski (PL) (479.05 KB - PDF)

View

português (PT) (396.78 KB - PDF)

View

română (RO) (469.9 KB - PDF)

View

slovenčina (SK) (502.71 KB - PDF)

View

slovenščina (SL) (463.36 KB - PDF)

View

Suomi (FI) (412.87 KB - PDF)

View

svenska (SV) (406.48 KB - PDF)

View

Latest procedure affecting product information: X/0009

16/05/2024

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (58.38 KB - PDF)

View

español (ES) (50.18 KB - PDF)

View

čeština (CS) (53.22 KB - PDF)

View

dansk (DA) (52.23 KB - PDF)

View

Deutsch (DE) (50.38 KB - PDF)

View

eesti keel (ET) (48 KB - PDF)

View

ελληνικά (EL) (55.99 KB - PDF)

View

français (FR) (51.14 KB - PDF)

View

hrvatski (HR) (53.95 KB - PDF)

View

íslenska (IS) (51.81 KB - PDF)

View

italiano (IT) (50.18 KB - PDF)

View

latviešu valoda (LV) (54.45 KB - PDF)

View

lietuvių kalba (LT) (53.47 KB - PDF)

View

magyar (HU) (53.24 KB - PDF)

View

Malti (MT) (53.92 KB - PDF)

View

Nederlands (NL) (49.39 KB - PDF)

View

norsk (NO) (51.56 KB - PDF)

View

polski (PL) (55.08 KB - PDF)

View

português (PT) (51.37 KB - PDF)

View

română (RO) (53.93 KB - PDF)

View

slovenčina (SK) (56.22 KB - PDF)

View

slovenščina (SL) (62.82 KB - PDF)

View

Suomi (FI) (49.85 KB - PDF)

View

svenska (SV) (50.32 KB - PDF)

View

Product details

Name of medicine
Lumykras
Active substance
sotorasib
International non-proprietary name (INN) or common name
sotorasib
Therapeutic area (MeSH)
Carcinoma, Non-Small-Cell Lung
Anatomical therapeutic chemical (ATC) code
L01XX73

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.

Authorisation details

EMA product number
EMEA/H/C/005522

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.

Marketing authorisation holder
Amgen Europe BV

Minervum 7061
4817ZK Breda
The Netherlands

Opinion adopted
11/11/2021
Marketing authorisation issued
06/01/2022
Revision
5

Assessment history

This page was last updated on

Share this page